Cognito Therapeutics Taps Eisai Veteran to Lead Alzheimer’s Portfolio
Event summary
- Thomas Fagan joins Cognito Therapeutics as Executive Vice President, Alzheimer’s Portfolio, effective March 11, 2026.
- Fagan brings 25 years of experience in Alzheimer’s diagnostics, therapeutics, and commercialization from Eisai and Eli Lilly.
- He will lead strategic planning and commercial readiness for Spectris™, Cognito’s lead neurostimulation therapy for Alzheimer’s.
- Fagan’s focus includes aligning clinical development, market preparation, and healthcare system engagement ahead of the pivotal HOPE trial.
- Previously led U.S. commercial strategy for Eisai’s LEQEMBI® (lecanemab) and Eli Lilly’s Amyvid (florbetapir).
The big picture
Cognito’s appointment of Thomas Fagan underscores its push toward commercialization as it nears pivotal trial data. Fagan’s background in Alzheimer’s diagnostics and therapeutics—particularly his role in launching Eisai’s LEQEMBI®—positions him to bridge clinical development and real-world adoption. The move signals Cognito’s intent to compete in a crowded Alzheimer’s market, where non-invasive therapies like Spectris™ could differentiate it from traditional drug-based approaches.
What we're watching
- Commercialization Strategy
- How Fagan’s experience with Eisai’s LEQEMBI® will shape Cognito’s approach to market readiness for Spectris™.
- Clinical Milestones
- The pace at which Cognito advances its pivotal HOPE trial and prepares for potential commercialization in 2027.
- Healthcare System Engagement
- Whether Cognito can effectively integrate Spectris™ into existing care models for Alzheimer’s patients.
Related topics